Royalty Pharma (RPRX) Cash from Investing Activities Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-114.28% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
826.39% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
-674.01% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
-194.83% |
| Date | Value |
|---|
| Mar 31, 2026 |
-194.83% |
| Dec 31, 2025 |
-67.69% |
| Sep 30, 2025 |
19.65% |
| Jun 30, 2025 |
65.07% |
| Mar 31, 2025 |
681.55% |
| Dec 31, 2024 |
49.45% |
| Sep 30, 2024 |
-164.66% |
| Jun 30, 2024 |
-1,308.06% |
| Mar 31, 2024 |
84.49% |
| Dec 31, 2023 |
-341.16% |
| Sep 30, 2023 |
68.38% |
| Jun 30, 2023 |
-110.20% |
| Mar 31, 2023 |
-5,102.47% |
| Dec 31, 2022 |
175.18% |
| Sep 30, 2022 |
-68.56% |
| Jun 30, 2022 |
-123.92% |
| Mar 31, 2022 |
101.86% |
| Dec 31, 2021 |
33.73% |
| Sep 30, 2021 |
8.12% |
| Jun 30, 2021 |
151.50% |
